SCHEMBL3399653

SCHEMBL3399653

Cc1nc(-c2cccc(C(C)C)c2)sc1C(=O)N1CCN(C(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.54
HTR2C P28335 7/20 0.47
KMT2A Q03164 1/20 0.44
THRA P10827 2/20 0.43
THRB P10828 2/20 0.43
PARP1 P09874 1/20 0.43
TRPM8 Q7Z2W7 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 2/20 0.42
ROCK1 Q13464 2/20 0.41
GSK3B P49841 2/20 0.39
GRK5 P34947 1/20 0.39
GSK3A P49840 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399805 0.89 CNR1 (0.56) CNR1HTR2CKMT2ATHRATHRB
SCHEMBL3404377 0.87 TRPM8 (0.57) CNR1HTR2CKMT2ATRPM8SMN1; SMN2
SCHEMBL3405550 0.87 CNR1 (0.55) CNR1HTR2CKMT2ATHRATHRB
SCHEMBL3401781 0.87 CNR1 (0.70) CNR1HTR2CKMT2APARP1SMN1; SMN2
SCHEMBL3402546 0.86 CNR1 (0.53) CNR1HTR2CKMT2ATHRATHRB
SCHEMBL3404549 0.86 CNR1 (0.53) CNR1HTR2CKMT2ATHRATHRB
SCHEMBL3400865 0.86 CNR1 (0.55) CNR1HTR2CTHRATHRBPARP1
SCHEMBL3403374 0.85 CNR1 (0.52) CNR1HTR2CKMT2ATHRATHRB
SCHEMBL3405128 0.85 CNR1 (0.52) CNR1HTR2CKMT2ATHRATHRB
SCHEMBL3399780 0.85 CNR1 (0.54) CNR1HTR2CKMT2ATHRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 CNR1 35/4885HTR2C 416/4885KMT2A 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.